StreetInsider.com News Articles

Vector Science and Therapeutics Corp. Announces Collaboration with SAFE Investment in Gary Payton's Scoreboard

Wed, 07 Oct 2026 09:54:00 -0400

Investment advances collaboration on peptide-based products for athletic performance, recovery and longevity

TORONTO, Oct. 7, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced that it has entered into a strategic relationship with Scoreboard, Inc. ("Scoreboard"), a performance wellness company co-founded by NBA Hall of Famer Gary Payton.

Vector Science and Therapeutics Corp. Announces Collaboration with SAFE Investment in Gary Payton's Scoreboard

Wed, 07 Oct 2026 09:54:00 -0400

Investment advances collaboration on peptide-based products for athletic performance, recovery and longevity

Vector Science and Therapeutics Corp. Issues Options

Fri, 25 Sep 2026 17:52:00 -0400

Mequon, Wisconsin--(Newsfile Corp. - September 25, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors has approved the grant of 150,000 stock options (the "Options") to an Officer of the Company in accordance with the Company's stock option plan. The Options vest in 25% tranches over a three year period, have an exercise price of C$1.80 and are exercisable for a period of five years from the date of grant. This grant of the Options is subject to the approval of the TSX Venture Exchange.

As of

Vector Science and Therapeutics Corp. Issues Options

Fri, 25 Sep 2026 17:52:00 -0400

As of

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

MEQUON, Wis., Aug. 25, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") is pleased to announce that the Company has entered into an investor relations agreement (the "IR Agreement") with RedChip Companies, Inc. ("RedChip") through its principal, Dave Gentry, dated August 24, 2026.

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options

Tue, 25 Aug 2026 20:27:00 -0400

Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online

Mon, 24 Aug 2026 07:30:00 -0400

55,000 vials of peptides will be produced from this production suite and are pre-sold
Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September

MEQUON, Wis., Aug. 24, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) (the "Company") today announced that the first of four planned manufacturing suites at its LyoGenesis Manufacturing facility is now producing pharma-grade peptides, putting the Company on track to begin fulfilling Vector's existing customer orders for nine peptides this month.

Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online

Mon, 24 Aug 2026 07:30:00 -0400

55,000 vials of peptides will be produced from this production suite and are pre-sold
Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September

Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online

Mon, 24 Aug 2026 07:30:00 -0400

55,000 vials of peptides will be produced from this production suite and are pre-sold
Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September

Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online

Mon, 24 Aug 2026 07:30:00 -0400

55,000 vials of peptides will be produced from this production suite and are pre-sold
Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September

Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides

Thu, 20 Aug 2026 07:30:00 -0400